Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988895 | 0.80 | LMNA (0.38) | LMNACYP2C19 | |
| SCHEMBL2984783 | 0.78 | SMN1; SMN2 (0.37) | LMNACYP2C19TDP1 | |
| SCHEMBL2646513 | 0.75 | POLB (0.43) | CYP2C19TDP1 | |
| SCHEMBL16761022 | 0.73 | ALDH1A1 (0.42) | LMNACYP2C19TDP1 | |
| SCHEMBL8644884 | 0.72 | LMNA (0.44) | LMNACYP2C19TDP1SLC1A3SLC1A2 | |
| SCHEMBL818254 | 0.72 | LMNA (0.39) | LMNACYP2C19TDP1SLC1A3SLC1A2 | |
| SCHEMBL3469382 | 0.70 | — | — | |
| SCHEMBL16245728 | 0.70 | LMNA (0.38) | LMNACYP2C19TDP1SLC1A3SLC1A2 | |
| SCHEMBL2462786 | 0.70 | SLC1A3 (0.39) | LMNACYP2C19SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8771744 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | LMNA 1700/4885CYP2C19 1053/4885TDP1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.